Clinical Decision Support Systems Market Insights: Enhancing Patient Outcomes Through Technology
Clinical Decision Support Systems Industry Overview
The global clinical decision support systems market size was estimated at USD 5.30 billion in 2023 and is projected to grow at a CAGR of 10.79% from 2024 to 2030. Clinical decision support systems (CDSSs) have experienced significant advancement in recent decades, providing clinicians with vital tools to make informed decisions in patient care. These systems have emerged as a promising means to improve patient outcomes and reduce overall healthcare costs.
Gather more insights about the market drivers, restrains and growth of the Clinical Decision Support Systems Market
AI and ML technologies are transforming the CDSS market, offering advanced functionalities such as predictive analytics, pattern recognition, and tailored recommendations. AI-driven CDSSs can analyze extensive datasets, detect patterns, anticipate outcomes, and suggest optimal treatment strategies. Researchers are integrating AI with CDSS, as demonstrated by the University of Texas at Austin’s Dell Medical School researchers who developed an AI-based CDSS to aid clinicians in discussing nutrition and making decisions with patients about diet improvements in December 2022.
The adoption of personalized medicine is increasing, with CDSSs playing a crucial role. These systems analyze patient data, including genetic profiles and medical histories, to customize treatment plans for individuals. By providing tailored recommendations, CDSSs enhance treatment effectiveness and reduce the risk of adverse reactions, driving market growth.
Governments worldwide are implementing regulations and incentives to promote CDSS and other healthcare IT solutions. These regulations focus on enhancing patient safety, interoperability, and care quality, prompting healthcare organizations to invest in CDSS to comply with regulatory requirements and qualify for incentives.
The COVID-19 pandemic has also positively impacted the market growth, leading to increased adoption of CDSS. CDSSs have been instrumental in supporting patient resources and services, as demonstrated by their role in real-time clinical diagnosis of COVID-19 and patient triage. Various countries offering online services have further fueled market growth. Market players have introduced CDSSs for managing COVID-19 data and insights. For instance, in May 2022, Epocrates launched an innovative tool for long COVID-19, integrating the latest updates to expand the collection of clinical decision support guidelines. Consequently, the increased adoption and introduction of clinical decision support systems have propelled market growth during the pandemic.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
The global biohacking market size was valued at USD 20.94 billion in 2023 and is projected to grow at a CAGR of 18.6% from 2024 to 2030. Factors expected to drive the growth of the biohacking market are the availability of wearable health trackers, genetic testing kits, smart devices, and apps that allow people to track and analyze their biometric data, leading to a more personalized and data-focused biohacking approach.
The global digital neuro biomarkers market size was estimated at USD 593.1 million in 2023 and is projected to grow at a CAGR of 25.3% from 2024 to 2030. The market is experiencing significant growth, driven by several key factors that reflect the increasing integration of technology in healthcare. These factors include the rising prevalence of chronic diseases, technological advancements, increased adoption of remote patient monitoring, growing focus on personalized medicine, and investment in research and development.
Clinical Decision Support Systems Market Segmentation
Grand View Research has segmented the global clinical decision support systems market report based on product, application, delivery mode, component, and region:
Clinical Decision Support Systems Product Outlook (Revenue, USD Million, 2018 - 2030)
Standalone CDSS
Integrated CPOE with CDSS
Integrated EHR with CDSS
Integrated CDSS with CPOE & EHR
Clinical Decision Support Systems Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug-drug interactions
Drug allergy alerts
Clinical reminders
Clinical guidelines
Drug dosing support
Others
Clinical Decision Support Systems Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)
Web-based Systems
Cloud-based Systems
On-premise Systems
Clinical Decision Support Systems Component Outlook (Revenue, USD Million, 2018 - 2030)
Hardware
Software
Services
Clinical Decision Support Systems Regional Outlook (Revenue, USD Million, 2018 - 2030)
Order a free sample PDF of the Clinical Decision Support Systems Market Intelligence Study, published by Grand View Research.
Key Companies profiled:
McKesson Corporation
Oracle (Cerner Corporation)
Siemens Healthineers GmbH
Allscripts Healthcare, LLC
athenahealth, Inc.
NextGen Healthcare Inc.
Koninklijke Philips N.V.
IBM
Agfa-Gevaert Group (IG Farben)
Wolters Kluwer N.V.
Recent Developments
In October 2023, Wolters Kluwer Health launched AI Labs, a collective resource to integrate generative AI with UpToDate, its CDS solution, enabling medical professionals to make better-informed decisions
In August 2023, GE HealthCare launched CardioVisio for Atrial Fibrillation, a patient-centric, digital CDS tool to allow precision care
In February 2023, EBSCO Information Services launched new features in DynaMedex Mobile App to improve clinical decision support. These enhancements improve the mobile experience for users by enabling clinicians to deliver evidence-based patient care efficiently
Moreover, in May 2020, DHIndia announced a partnership with EHRC@IIITB & Healthelife to develop a CDSS for the screening of COVID-19. The partnership also included the formation of a minimal triage application for front-line doctors
In March 2020, IBM Watson Health partnered with EBSCO Information Services to enhance CDSS and operations for healthcare systems and providers
Komentarze